Sheldon L. Koenig - 14 Mar 2022 Form 4 Insider Report for Esperion Therapeutics, Inc. (ESPR)

Role
President and CEO, Director
Signature
/s/ Richard B. Bartram, by power of attorney
Issuer symbol
ESPR
Transactions as of
14 Mar 2022
Net transactions value
$0
Form type
4
Filing time
16 Mar 2022, 17:08:37 UTC
Previous filing
01 Nov 2021
Next filing
18 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ESPR Common Stock Award $0 +116,000 +146% $0.000000 195,288 14 Mar 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ESPR Stock Option (right to buy 492,000 14 Mar 2022 Common Stock 492,000 $4.74 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The awards will vest quarterly over four years beginning on March 15, 2022.
F2 Consists of 195,288 shares of common stock held, including 2,588 shares acquired in Esperion's Employee Stock Purchase Plan.